Actavis

02/26/2014

Pay-for-Delay Tactics of Drug Manufacturers Considered by Supreme Court

Pay for Delay Drug Costs

The debate over "reverse payment" patent litigation settlements continues following the Supreme Court's decision in FTC v. Actavis that such agreements should be individually evaluated to determine whether they violate the anti-trust laws. Reverse payment settlements (aptly referred to as pay-for-delay settlements) arise when a brand drug manufacturer sues a generic drug maker for patent infringement and settles the litigation by paying the generic drug manufacture not to bring the lower-cost generic drug to market for a specified period of time,... Read More